Legal psychedelic therapy services, trials and training
Regulated clinical services, recruiting clinical trials and professional training. Global coverage, with the UK and Europe first. Every listing links to a primary source and shows the date we last checked it.
United Kingdom
13 listings
Clerkenwell Health
Clinical research organisation and trial site in central London that delivers psychedelic clinical trials for sponsors. It offers research participation only, not treatment outside trials.
Oxford Health NHS Interventional Psychiatry Service
NHS-run specialist service at the Warneford Hospital offering assessment and specialist treatment for adults with treatment-resistant depression, on referral from a GP or psychiatrist. Usually self-funded; NHS funding is available only for eligible Oxfordshire and Buckinghamshire patients.
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Phase 3 study registered on ClinicalTrials.gov. Condition: Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder. Interventions listed: CYB003; Psychological Support. Lead sponsor: Cybin IRL Limited. Sites in: Australia, Czechia, Germany, Greece, Ireland, Poland and 2 more (79 sites).
Ketamine for depression with anorexia nervosa (feasibility RCT)
Randomised controlled feasibility study in adults with long-standing anorexia nervosa and severe depression that has not responded to treatment. Condition: Depression with anorexia nervosa. Sponsor/lead site: King's College London. Funder: Medical Research Council. Recruitment window on ISRCTN: 1 Aug 2025 – 1 Oct 2027.
MORE-KARE: ketamine-assisted psychological therapy to reduce alcohol relapse
Multi-centre trial investigating whether ketamine-assisted psychological therapy increases abstinence in severe alcohol use disorder. Condition: Severe alcohol use disorder. Sponsor/lead site: University of Exeter (multi-centre NHS sites). Recruitment window on ISRCTN: 25 Jun 2024 – 31 Dec 2026.
PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm
Early phase 1 study registered on ClinicalTrials.gov. Condition: Self Harm. Interventions listed: Psilocybin 5 mg with cognitive behavioural therapy intervention; Placebo with cognitive behavioural therapy intervention. Lead sponsor: Imperial College London. Sites in: United Kingdom (1 site).
PsilOpioid: psilocybin therapy in opioid use disorder
Proof-of-concept randomised controlled trial of psilocybin therapy and brain reward mechanisms in opioid use disorder. Condition: Opioid use disorder. Sponsor/lead site: Imperial College London (NIHR Imperial Clinical Research Facility). Funder: National Institute for Health and Care Research. Recruitment window on ISRCTN: 13 Nov 2025 – 6 Jan 2027.
Sleep Blinding Psilocybin: feasibility study
Feasibility study testing whether participants can tell if they received psilocybin or placebo when the dose is given to act during sleep. Condition: Depression. Sponsor/lead site: South London and Maudsley NHS Foundation Trust. Funder: Medical Research Council. Recruitment window on ISRCTN: 1 Jun 2026 – 1 Jun 2028.
Imperial College London: Centre for Psychedelic Research
Academic research centre running clinical and neuroscience studies of psychedelics. It is a source of UK trial opportunities, including PsiloIMAGINE and PsilOpioid.
King's College London: Psychoactive Trials Group
Clinical research group at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) running controlled trials of psychedelic and related compounds for conditions including treatment-resistant depression and PTSD.
University of Exeter: Psychedelic Interdisciplinary Centre (EPIC)
Interdisciplinary university centre covering clinical psychopharmacology, social science and humanities research on psychedelics. It is linked to UK addiction trials and to Exeter's PGCert in Psychedelics.
PsyEdu: Professional Certificate in Psychedelic Practice
One-year professional certificate for registered health and social care professionals, delivered online with in-person weekends. It is endorsed by Drug Science. Standard fee £6,200 (including a £300 enrolment fee), with instalments available.
University of Exeter: PGCert Psychedelics (Mind, Medicine, and Culture)
Part-time online postgraduate certificate of up to 12 months covering psychopharmacology, therapy, neuroscience, anthropology, ethics and research methods. It is an academic rather than practical qualification. Fee £5,000.
Europe
31 listings
National Institute of Mental Health (NUDZ)
Czech national mental health institute preparing to introduce psychedelic-assisted therapy under Czechia's new legal framework, which since 1 January 2026 allows treatment only in specialised healthcare facilities under a binding clinical protocol. NUDZ says it is not yet possible to apply or join a waiting list.
Psyon
Prague healthcare clinic with a multidisciplinary team experienced in psychedelic-assisted therapy. It has announced plans to provide treatment under Czechia's regulated framework and is collecting expressions of interest. It also co-sponsors the RAFAEL clinical trial.
Central Institute of Mental Health (ZI) Mannheim: compassionate use programme
University psychiatric institute running Germany's BfArM-approved compassionate use (Härtefall) programme for adults with treatment-resistant depression who cannot join a clinical trial. Treatment is inpatient, with outpatient eligibility checks, preparation and follow-up. Each case is assessed individually.
OVID Clinic Berlin
Psychiatric day clinic and the second site of Germany's BfArM-approved compassionate use programme for adults with treatment-resistant depression, under the direction of Prof. Gerhard Gründer. Each case is assessed individually.
Geneva University Hospitals (HUG): addiction service
Public university hospital addiction service offering psychedelic-assisted psychotherapy under Swiss FOPH limited-medical-use authorisation. It is for adults living in Switzerland with treatment-resistant anxiety, depression or addiction who are already in psychotherapy.
Psychiatric University Hospital Zurich (PUK): second-opinion depression clinic
University hospital outpatient clinic offering psychedelic-assisted therapy for severe treatment-resistant depression under individual BAG authorisation. Patients must have had at least two unsuccessful guideline treatments and be in ongoing psychotherapy; treatment includes a short inpatient stay.
SÄPT: Swiss Medical Society for Psychedelic-Assisted Therapy
Professional society that publishes a list of therapists who have carried out BAG-authorised psychedelic-assisted therapy in Switzerland, with guidance for patients. Capacity is very limited and treatment is open only to Swiss residents.
UPK Basel Privatklinik: psychedelic-assisted therapy
University psychiatric hospital's private clinic offering psychedelic-assisted therapy under individual Swiss federal (BAG/FOPH) exceptional authorisations. It is for patients whose conventional treatment has not helped, and is delivered as a structured inpatient programme.
Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects
Phase 1 study registered on ClinicalTrials.gov. Condition: Depression - Major Depressive Disorder, Anhedonia. Interventions listed: Psilocybin (Usona Institute); Risperidone 1 MG; MRI. Lead sponsor: Medical University of Vienna. Sites in: Austria (1 site).
Ketamine in OCD: Efficacy and Effects on Stress and Cognition
Observational/other study registered on ClinicalTrials.gov. Condition: Obsessive-Compulsive Disorder, Psychiatric Disorder. Interventions listed: Ketamine 50 MG/ML Blinded; Midazolam; Ketamine 50 MG/ML Open Label. Lead sponsor: Medical University of Vienna. Sites in: Austria (1 site).
Psilocybin Therapy for Psychological Distress in Palliative Patients
Phase 2 study registered on ClinicalTrials.gov. Condition: COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis). Interventions listed: Psilocybin therapy. Lead sponsor: University Medical Center Groningen. Sites in: Czechia, Denmark, Netherlands, Portugal (4 sites).
Efficacy of psilocybin and trazodone combination in treatment-resistant depression: a randomized controlled proof-of-concept study (PSILOTRAZ)
Clinical trial authorised in the EU Clinical Trials Information System (CTIS). Condition: Treatment-resistant depression. Sponsor: Groupe Hospitalier Universitaire Paris Psychiatrie & Neuroscience. Sites: GHU St Anne Psychiatrie et Neurosciences (Paris). Estimated end: 2029-04-14.
ERPPAD - Efficacy in Relapse Prevention: Psilocybin in Alcohol use disorder with Depressive symptoms
Clinical trial authorised in the EU Clinical Trials Information System (CTIS). Condition: Alcohol use disorder, depressive symptoms. Sponsor: Centre Hospitalier Universitaire De Nimes. Sites: Centre Hospitalier De La Cote Basque (Bayonne); Centre Hospitalier Universitaire De Nimes (Nimes); Centre Hospitalier Regional Et Universitaire De Brest (Brest Cedex 2); Centre Hospitalier Universitaire De Saint Etienne (Saint Priest En Jarez). Estimated end: 2030-12-31.
Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a pilot study
Clinical trial authorised in the EU Clinical Trials Information System (CTIS). Condition: Gambling disorder. Sponsor: Centre Hospitalier Universitaire De Nantes. Sites: Centre Hospitalier Universitaire De Nantes (Nantes). Estimated end: 2028-09-01.
Pharmacologic Treatment Augmentation in Chronic Depression
Phase 2 study registered on ClinicalTrials.gov. Condition: Major Depressive Disorder. Interventions listed: Ketamine; Placebo; CBASP. Lead sponsor: University Hospital Tuebingen. Sites in: Germany (2 sites).
POSITRON - PsilOcybin with pSychologIcal supporT foR cOcaiNe: a randomised controlled pilot feasibility trial of psilocybin with psychological support for cocaine use disorder
Clinical trial authorised in the EU Clinical Trials Information System (CTIS). Condition: Cocaine addiction. Sponsor: Trinity College Dublin. Sites: Tallaght Adult Mental Health Service (Dublin 24); Wellcome HRB Clinical Research Facility (Dublin 8). Estimated end: 2028-07-28.
Ketamine Augmentation of ECT in Treatment-Resistant Depression
Phase 3 study registered on ClinicalTrials.gov. Condition: Major Depressive Disorder, Treatment Resistant Depression. Interventions listed: Ketamine Hydrochloride; Placebo. Lead sponsor: Università Vita-Salute San Raffaele. Sites in: Italy (1 site).
Psilocybin versus Personalized Neuromodulation for Resistant Depression (PSILO-MODULATION)
Clinical trial authorised in the EU Clinical Trials Information System (CTIS). Condition: Treatment Resistant Depression (TRD). Sponsor: Universita' Degli Studi G. D'Annunzio Di Chieti. Sites: Universita' Degli Studi G. D'Annunzio Di Chieti (Chieti Scalo); ASL Roma 5 (Colleferro (RM)); Azienda Ospedaliero Universitaria - Policlinico Riuniti Foggia (Foggia). Estimated end: 2027-05-30.
Trazodone’s Effects on Moderation of Psilocybin Outcomes (TEMPO)
Clinical trial authorised in the EU Clinical Trials Information System (CTIS). Condition: Treatment-Resistant Depression. Sponsor: Universita' Degli Studi G. D'Annunzio Di Chieti. Sites: Universita' Degli Studi G. D'Annunzio Di Chieti (Chieti Scalo). Estimated end: 2026-12-31.
High-Intensity Inpatient MDMA-Assisted Psychotherapy for Treatment-Refractory Posttraumatic Stress Disorder: An Open-Label Pilot Study
Clinical trial authorised in the EU Clinical Trials Information System (CTIS). Condition: posttraumatic stress disorder. Sponsor: Arq National Psychotrauma Centre. Sites: Arq National Psychotrauma Centre (Diemen). Estimated end: 2026-12-31.
LSD to Improve Cluster Headache Impact Trial
Phase 2 study registered on ClinicalTrials.gov. Condition: Chronic Cluster Headache. Interventions listed: LSD tartrate; Placebo. Lead sponsor: Radboud University Medical Center. Sites in: Netherlands (2 sites).
Working Mechanisms and Effectiveness of IV Ketamine-assisted Psychotherapy on Depression in TRD Clients
Observational/other study registered on ClinicalTrials.gov. Condition: Treatment Resistant Depression. Lead sponsor: Senz. Sites in: Netherlands (1 site).
Ketamine for Combined Depression and Alcohol Use Disorder
Phase 1, Phase 2 study registered on ClinicalTrials.gov. Condition: Depression, Alcohol Use Disorder. Interventions listed: Ketamine Hydrochloride; Midazolam Hydrochloride. Lead sponsor: University Hospital of North Norway. Sites in: Norway (1 site).
A double-blind, randomized, controlled trial on the effect of PEX010 for prolonged grief disorder
Clinical trial authorised in the EU Clinical Trials Information System (CTIS). Condition: Prolonged grief disorder. Sponsor: Linkopings Universitet. Sites: Region Oestergoetland (Linkoping). Estimated end: 2028-04-01.
Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa
Phase 2 study registered on ClinicalTrials.gov. Condition: Anorexia Nervosa. Interventions listed: Psilocybin. Lead sponsor: Region Skane. Sites in: Sweden (1 site).
Antidepressant Response of DMT Masked With Propofol
Observational/other study registered on ClinicalTrials.gov. Condition: Major Depressive Disorder, Psychedelic Experiences. Interventions listed: N,N-Dimethyltryptamine; Placebo; Propofol. Lead sponsor: University Hospital, Basel, Switzerland. Sites in: Switzerland (1 site).
LSD Treatment for Persons With Alcohol Use Disorder
Phase 2 study registered on ClinicalTrials.gov. Condition: Alcohol Use Disorder (AUD). Interventions listed: LSD; Active placebo. Lead sponsor: Felix Mueller. Sites in: Switzerland (2 sites).
Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache
Phase 2 study registered on ClinicalTrials.gov. Condition: Cluster Headache. Interventions listed: Lysergic Acid Diethylamide; Placebo. Lead sponsor: University Hospital, Basel, Switzerland. Sites in: Switzerland (1 site).
Lysergic Acid Diethylamide (LSD) in Palliative Care
Phase 2 study registered on ClinicalTrials.gov. Condition: Palliative Care, Pain, Anxiety. Interventions listed: Lysergic Acid Diethylamide Tartrate; Lysergic Acid Diethylamide Tartrate. Lead sponsor: University Hospital, Basel, Switzerland. Sites in: Switzerland (4 sites).
MIND Foundation: Augmented Psychotherapy Training (APT)
15-month hybrid professional training in psychedelic-assisted therapy, with three on-site intensive weeks in Berlin and weekly online sessions. The next English course starts 7 November 2026 and the next German course on 13 March 2027.
SÄPT Academy: three-year curriculum in psychedelic-assisted therapy
Continuing education calendar and a three-year postgraduate curriculum (Weiterbildung PAT) in the theory and practice of psychedelic-assisted therapy, run by the Swiss professional society.
Rest of the world
15 listings
EMPAX Centre
Specialist clinic in Perth and Fremantle, with TGA Authorised Prescriber psychiatrists under Australia's controlled-access scheme for PTSD and treatment-resistant depression.
Evolution Medicine Enhanced Therapy
Sydney programme of medically supervised therapy for PTSD and treatment-resistant depression, with intensive therapy days at Hirondelle Private Hospital, Chatswood. It is led by a TGA Authorised Prescriber psychiatrist under Australia's controlled-access scheme.
Mind Medicine Australia Clinic
Clinic and centre of excellence with TGA Authorised Prescriber psychiatrists working under Australia's controlled-access scheme for treatment-resistant depression and PTSD.
Monarch Mental Health Group
Psychiatry group with clinics in Sydney and Canberra, with a TGA Authorised Prescriber psychiatrist under Australia's controlled-access scheme. It also runs clinical trials.
Proteus Clinic
Psychiatric service based at Belmont Private Hospital, with TGA Authorised Prescriber psychiatrists under Australia's controlled-access scheme for complex mood disorders.
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Phase 2, Phase 3 study registered on ClinicalTrials.gov. Condition: PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms. Interventions listed: COMP360 psilocybin. Lead sponsor: COMPASS Pathways. Sites in: Canada, United States (9 sites).
MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder
Phase 2, Phase 3 study registered on ClinicalTrials.gov. Condition: Post Traumatic Stress Disorder, Alcohol Use Disorder. Interventions listed: Full Dose MDMA; MDMA-Assisted psychotherapy; Active Placebo Dose MDMA. Lead sponsor: VA Office of Research and Development. Sites in: United States (2 sites).
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
Phase 3 study registered on ClinicalTrials.gov. Condition: Major Depression. Interventions listed: Psilocybin; Psilocybin. Lead sponsor: VA Office of Research and Development. Sites in: United States (5 sites).
Johns Hopkins Center for Psychedelic & Consciousness Research
Major US academic research centre running clinical and basic studies of psychedelics. It lists studies that are recruiting volunteers.
NYU Langone Center for Psychedelic Medicine
Academic centre conducting translational and clinical research on psychedelics for addiction, depression, PTSD and cancer-related distress.
UC Berkeley Center for the Science of Psychedelics
University centre for psychedelic research, public education (The Microdose newsletter) and training of psychedelic facilitators for research settings.
Mind Medicine Australia: Certificate in Psychedelic-Assisted Therapies (CPAT)
Hybrid certificate for psychiatrists, therapists and other health professionals, with clinical experience available at the Mind Medicine Australia Clinic. Course fee A$10,950 in instalments or A$9,950 paid upfront. The next cohort begins 21 February 2027.
CIIS: Certificate in Psychedelic-Assisted Therapies and Research
12-month hybrid or online certificate for licensed clinicians, researchers, clergy and related professionals. Tuition is $9,400 (hybrid) or $8,900 (online). The 2026–27 cohort is closed and the 2027–28 application cycle opens on 15 January 2027.
Fluence: Psychedelic Therapy Education
Online continuing education in psychedelic therapy and integration for clinicians. Pre-enrolment is open for a post-approval certificate programme tied to an investigational psychedelic therapy.
Integrative Psychiatry Institute: Psychedelic-Assisted Therapy Training
Year-long professional training and certification in psychedelic-assisted therapy for licensed mental health and medical professionals.
About this directory. Psyche Insights lists organisations for information only. A listing is not an endorsement, a recommendation or medical advice, and we do not take referral fees. We list only lawful, regulated services, registered clinical trials and professional training. We do not list retreats or anyone offering psychedelics outside the law. Psilocybin, MDMA, LSD and DMT are controlled drugs in the UK. Eligibility, availability and legal status differ by country and change often. Always check details with the provider or trial team, and talk to your GP or specialist before making any treatment decision. Paid placements are labelled “Featured · Paid placement” and never change our editorial descriptions. See our terms.
Corrections and removal. Spotted an error, or represent a listed organisation and want a listing corrected, updated or removed? Email [email protected] with the page link and the change needed. We aim to reply within 5 working days.
Get every update in your inbox
Each week Psyche Insights covers new trials, approvals and access changes, starting with the UK and Europe.
Subscribe free → New to this? Read our guides: UK psilocybin trials · UK legal status. Run a regulated service, trial or course? Get listed or claim your listing.